These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 32892058)
1. Is DNA repair a potential target for effective therapies against malignant mesothelioma? Fuso Nerini I; Roca E; Mannarino L; Grosso F; Frapolli R; D'Incalci M Cancer Treat Rev; 2020 Nov; 90():102101. PubMed ID: 32892058 [TBL] [Abstract][Full Text] [Related]
2. A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design. Passiglia F; Bironzo P; Righi L; Listì A; Arizio F; Novello S; Volante M; Scagliotti GV Clin Lung Cancer; 2021 Jan; 22(1):e63-e66. PubMed ID: 32917522 [TBL] [Abstract][Full Text] [Related]
3. Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma. Morra F; Merolla F; D'Abbiero D; Ilardi G; Campione S; Monaco R; Guggino G; Ambrosio F; Staibano S; Cerrato A; Visconti R; Celetti A Lung Cancer; 2019 Sep; 135():56-65. PubMed ID: 31447003 [TBL] [Abstract][Full Text] [Related]
5. Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro. Borchert S; Wessolly M; Schmeller J; Mairinger E; Kollmeier J; Hager T; Mairinger T; Herold T; Christoph DC; Walter RFH; Eberhardt WEE; Plönes T; Wohlschlaeger J; Aigner C; Schmid KW; Mairinger FD BMC Cancer; 2019 Jan; 19(1):108. PubMed ID: 30700254 [TBL] [Abstract][Full Text] [Related]
6. A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair. Parrotta R; Okonska A; Ronner M; Weder W; Stahel R; Penengo L; Felley-Bosco E J Thorac Oncol; 2017 Aug; 12(8):1309-1319. PubMed ID: 28389374 [TBL] [Abstract][Full Text] [Related]
7. [Abnormalities of DNA repair and gynecological cancers]. Auguste A; Leary A Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544 [TBL] [Abstract][Full Text] [Related]
8. Resurrection of PARP Inhibitors in Breast Cancer. Lyons TG; Robson ME J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424 [TBL] [Abstract][Full Text] [Related]
9. The current status of PARP inhibitors in ovarian cancer. McLachlan J; George A; Banerjee S Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873 [TBL] [Abstract][Full Text] [Related]
10. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors. Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618 [TBL] [Abstract][Full Text] [Related]
11. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells. Senhaji Mouhri Z; Goodfellow E; Jean-Claude B BMC Cancer; 2017 Aug; 17(1):540. PubMed ID: 28800752 [TBL] [Abstract][Full Text] [Related]
12. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside. Turk AA; Wisinski KB Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759 [TBL] [Abstract][Full Text] [Related]
13. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226 [TBL] [Abstract][Full Text] [Related]
15. Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM). Lapidot M; Case AE; Weisberg EL; Meng C; Walker SR; Garg S; Ni W; Podar K; Hung YP; Carrasco RD; Knott A; Gokhale PC; Sharma S; Pozhitkov A; Kulkarni P; Frank DA; Salgia R; Griffin JD; Saladi SV; Bueno R; Sattler M Br J Cancer; 2021 Aug; 125(4):582-592. PubMed ID: 34088988 [TBL] [Abstract][Full Text] [Related]
16. PARP Inhibitors: The Cornerstone of DNA Repair-Targeted Therapies. del Rivero J; Kohn EC Oncology (Williston Park); 2017 Apr; 31(4):265-73. PubMed ID: 28412778 [TBL] [Abstract][Full Text] [Related]
17. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. Gourley C; Balmaña J; Ledermann JA; Serra V; Dent R; Loibl S; Pujade-Lauraine E; Boulton SJ J Clin Oncol; 2019 Sep; 37(25):2257-2269. PubMed ID: 31050911 [TBL] [Abstract][Full Text] [Related]
18. [Advances in Targeted Therapy for Malignant Pleural Mesothelioma]. Fu F; Zhang Y; Shen H Zhongguo Fei Ai Za Zhi; 2024 May; 27(5):391-398. PubMed ID: 38880927 [TBL] [Abstract][Full Text] [Related]
19. Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae. Kalimutho M; Bain AL; Mukherjee B; Nag P; Nanayakkara DM; Harten SK; Harris JL; Subramanian GN; Sinha D; Shirasawa S; Srihari S; Burma S; Khanna KK Mol Oncol; 2017 May; 11(5):470-490. PubMed ID: 28173629 [TBL] [Abstract][Full Text] [Related]
20. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers. Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942 [No Abstract] [Full Text] [Related] [Next] [New Search]